DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/wspc2j/research_report) has announced the addition of the "Concise Analysis of the International and China Monoclonal Antibody Industry" report to their offering.
Monoclonal antibody still belongs to high-end products in China market, which mainly depends on import. In 2012, the market scale of monoclonal antibody was only over CNY 2 billion, which accounted for less than 1% of the global market share but the growth rate was rather high. Roche is the largest winner in China monoclonal antibody market with the market shares of its Rituximab and Trastuzumab being the largest. Merck and Novartis also occupy rather large market shares.
Take Rituximab and Trastuzumab that were produced and sold by Roche at an earlier time for instance, their sales values in sample hospitals were only CNY 17.70 million and CNY 2.70 million respectively in 2003, which increased to CNY 590 million and CNY 530 million in 2011. In 2012, the sales value of Etanercept produced by China native enterprises exceeded CNY 400 million, with net profit approximating CNY 200 million and profit margin far exceeding that of other biological drugs. Currently, China domestic monoclonal antibody drugs are still in the initial stage and only nine kinds of drugs have been sold in the market.
Most drug varieties that are in clinical study or have been sold are complete copies of products sold overseas with rather low production level and small scale, which restricts the domestic development of monoclonal antibody drugs.
Key Topics Covered:
1 Relevant Concepts of Monoclonal Antibody
2 Overview on Global Monoclonal Antibody Market, 2008-2012
3 Performance of China Monoclonal Antibody Market, 2008- 2012
4 Top 5 Native Monoclonal Antibody Enterprises in China, 2011-2013
5 Market Prospect of Monoclonal Antibody in China, 2013-2017
For more information visit http://www.researchandmarkets.com/research/wspc2j/research_report
Source: Research and Markets